FDA approval fueled a stock price surge for Geron Corporation.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approval fueled a stock price surge for Geron Corporation.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Geron Corporation
company
Nothing else this week.
Related events
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- FDA raised concerns over cell therapy evidence for Capricor Therapeutics, causing a sharp drop in stock price.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- ADC Therapeutics is seeking accelerated approval from the FDA for its Zynlonta therapy.
- FDA clearance drives market expansion and coverage for NeurAxis, Inc.